Page 30 - 2019_07 resto del Mondo-web

K.D. Cummins et al. 371(16):1507-1517.
28. Kim MY, Yu KR, Kenderian SS, et al. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018;173(6):1439-1453.e19.
29. Gale RP, Sparkes RS, Golde DW. Bone Marrow Origin of Hepatic Macrophages (Kupffer Cells) in Humans. Science. 1978;201(4359):937-938.
30. Thomas ED, Ramberg RE, Sale GE, et al. Direct Evidence for a Bone Marrow Origin of the Alveolar Macrophage in Man. Science. 1976;192(4243):1016-1018.
31. Takahashi K, Kakuda Y, Munemoto S, et al. Differentiation of Donor-Derived Cells Into Microglia After Umbilical Cord Blood Stem Cell Transplantation. J Neuropathol Exp Neurol. 2015;74(9):862-866.
32. Godwin CD, McDonald GB, Walter RB. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood. 2017;129(16):2330-2332.
33. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 2014;28(4):143-153.
34. Lowe KL, Mackall CL, Norry E, et al. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018 2018;25(3):176-191.
35. Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood. 2016;127(26):3305.
36. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engi- neered T cells mediate sustained antigen- specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921.
37. Alexandrov LB, Nik-Zainal S, Wedge DC, et
al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415- 421.
38. Xue S, Gao L, Gillmore R, et al. WT1-target- ed immunotherapy of leukaemia. Blood Cells Mol Dis. 2004 2004;33(3):288-290.
39. Tawara I, Kageyama S, Miyahara Y, et al. Safety and persistence of WT1-specific T- cell receptor gene−transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985.
in remission is associated with induction of antileukemia immunity and prolonged remis- sions. Sci Transl Med. 2016;8(368): 368ra171.
46. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5): 478-488.
47. Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer. 2013;1(13).
48. Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol. 2016;103:62-77.
49. Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016;14:357-362.
50. D’Aloia MM, Zizzari IG, Sacchetti B, et al. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9(3):282.
51. Turtle CJ, Hanafi L-A, Berger C, et al. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood. 2015;126(23):3773.
52. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ com- position in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-2138.
53. Morgan R, Yang J, Kitano M, et al. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther. 2010;18(4): 843-851.
40. Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5(174):174ra27.
41. Brodská B, Fuchs O, Otevřelová P, et al. PD- L1 Is Frequently Expressed in Acute Myeloid Leukemia Patients with Leukocytosis. Blood. 2016;128(22):5229.
42. Daver N, Basu S, Garcia-Manero G, et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood. 2016;128(22):763.
43. Uttenthal B, Martinez-Davila I, Ivey A, et al. Wilms' Tumour 1 (WT1) peptide vaccina- tion in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol. 2014;164(3):366-375.
44. Rosenblatt J, Stone RM, Uhl L, et al. DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. Blood. 2015;126(23):2549.
45. Rosenblatt J, Stone RM, Uhl L, et al. Individualized vaccination of AML patients
1308
haematologica | 2019; 104(7)